• Follow
  • Follow
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise

Log in

Start free trial
G2 Intelligence
  • Reports
    • Lab Industry Advisor
      • Essentials Reports
      • Premium Reports
      • Elite Reports
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Articles
    • Lab Industry Advisor
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Webinars
  • Store
Diagnostics Pipeline: Roche’s New Cobas Liat Panel Can Test for Multiple STIs Simultaneously

Diagnostics Pipeline: Roche’s New Cobas Liat Panel Can Test for Multiple STIs Simultaneously

by Ron Shinkman | Mar 11, 2025 | Clinical Diagnostics Insider, Diagnostic Testing and Emerging Technologies, Emerging Tests-dtet

The PCR-driven test provides results in about 20 minutes in non-laboratory settings

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
Diagnostics Pipeline: 2024 Trends in FDA Approvals

Diagnostics Pipeline: 2024 Trends in FDA Approvals

by Rachel Muenz | Jan 6, 2025 | Clinical Diagnostics Insider, FDA-dtet

In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
A Lasting Impact: COVID-19 and Cancer Screening

A Lasting Impact: COVID-19 and Cancer Screening

by Michael Schubert, PhD | Dec 17, 2024 | Clinical Diagnostics Insider, Testing Trends-dtet

Several years after the onset of the COVID-19 pandemic, labs are still dealing with the effects of missed and delayed screenings

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
How the LDT Final Rule’s Exemptions Apply to Oncology Labs

How the LDT Final Rule’s Exemptions Apply to Oncology Labs

by Scott Wallask | Nov 7, 2024 | Compliance Perspectives-lca, Compliance-lca, Essential, FDA-lca, Lab Industry Advisor

Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
FDA Watch: FDA Approves Enhanced Cologuard Cancer Test

FDA Watch: FDA Approves Enhanced Cologuard Cancer Test

by Ron Shinkman | Nov 1, 2024 | CDC-nir, Essential, FDA-lca, Lab Industry Advisor

Test maker Exact Sciences says it expects Cologuard Plus to cut false positives by more than 30 percent

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
« Older Entries

Log In

Join Now | Lost Password?
  • Follow
  • Follow
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise
Copyright © 2025 G2Intelligence.com